BIOGEN INC CEDEAR EACH 13 REP 1 COM USD0.0005BIOGEN INC CEDEAR EACH 13 REP 1 COM USD0.0005BIOGEN INC CEDEAR EACH 13 REP 1 COM USD0.0005

BIOGEN INC CEDEAR EACH 13 REP 1 COM USD0.0005

No trades
See on Supercharts

Key stats

Market capitalization
‪31.67 B‬USD
Dividend yield (indicated)
Price to earnings Ratio (TTM)
Basic EPS (TTM)
Net income (FY)
Revenue (FY)
Shares float
Beta (1Y)
0.52

About Biogen Inc.

CEO
Christopher A. Viehbacher
Headquarters
Cambridge
Website
Founded
1978
ISIN
ARBCOM4601A8
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where BIIBC is featured.